Clinical Trial Update: Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating eribulin mesylate combined with lobaplatin for recurrent or metastatic triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ERIBULIN MESYLATE (Eribulin mesylate)
• Lobaplatin (lobaplatin)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN